Actinium Pharmaceuticals Announces Participation in Stephens Biotechnology Virtual Fireside Chat

Actinium Pharmaceuticals, Inc. (ATNM) has announced that Sandesh Seth, Chairman and CEO, will participate in the Stephens Biotechnology Virtual Fireside Chat on November 4, 2025. During the conference, members of the company's management team will be available for one-on-one meetings with investors. This event comes as the company continues to advance its pipeline of targeted radiotherapies, with lead product candidate ATNM-400 demonstrating promising results in preclinical studies for the treatment of prostate cancer and non-small cell lung cancer.

Key Takeaways:

• Actinium Pharmaceuticals is developing a pipeline of targeted radiotherapies, with lead product candidate ATNM-400 showing potential in preclinical studies for the treatment of prostate cancer and non-small cell lung cancer.
• ATNM-400 has demonstrated tumor-specific uptake, higher efficacy than androgen receptor inhibitor enzalutamide, and durable tumor control in prostate cancer models resistant to both enzalutamide and 177Lu-PSMA-617 radiotherapy.
• The data generated to date with ATNM-400 supports its potential across treatment settings to be used either as a monotherapy, or in combination or sequenced with other therapies.
• Actinium's most advanced product candidate in development is Actimab-A, a CD33 targeting therapeutic, which has demonstrated potential activity in relapsed and refractory acute myeloid leukemia (AML) patients.
• Actinium is engaged with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) for the development of Actimab-A in AML and other myeloid malignancies.
• The company is developing Actimab-A as a potential pan tumor therapy in combination with PD-1 checkpoint inhibitors, which represents a potential multi-billion-dollar addressable market.
• Iomab-ACT, a next-generation conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies.

Statistics:

• Approximately 240 patents and patent applications are held by Actinium, including several related to the manufacture of the isotope Ac-225 in a cyclotron.
• Actimab-A has demonstrated high rates of Complete Remissions (CR) and measurable residual disease (MRD) negativity in relapsed and refractory acute myeloid leukemia (r/r AML) patients when used in combination with the chemotherapy CLAG-M.
• The company is advancing several preclinical programs for solid tumor indications.
• Actinium is seeking a potential strategic partner for the U.S. commercialization of Iomab-B, an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML.

Sources:

• Actinium Pharmaceuticals, Inc. (2025) - "Actinium Pharmaceuticals Announces Participation in Stephens Biotechnology Virtual Fireside Chat"
• Actinium Pharmaceuticals, Inc. - Investor Relations
• Actinium Pharmaceuticals, Inc. - Forward-Looking Statements (2025) - "Private Securities Litigation Reform Act of 1995"
• Actinium Pharmaceuticals, Inc. - Form 10-K (2022)
• Actinium Pharmaceuticals, Inc. - Form 8-K (2022)
• Actinium Pharmaceuticals, Inc. - Press Releases